Basit öğe kaydını göster

dc.contributor.authorKayıkçıoğlu, M.
dc.contributor.authorTokgözoğlu, L.
dc.contributor.authorMutluer, F.O.
dc.contributor.authorUral, D.
dc.contributor.authorBiteker, Murat
dc.date.accessioned2020-11-20T16:46:17Z
dc.date.available2020-11-20T16:46:17Z
dc.date.issued2018
dc.identifier.issn1016-5169
dc.identifier.urihttps://doi.org/10.5543/tkda.2018.53248
dc.identifier.urihttps://hdl.handle.net/20.500.12809/5651
dc.descriptionPubMed ID: 29339690en_US
dc.description.abstractObjective: Peripartum cardiomyopathy (PPCM) is left ventricular (LV) systolic dysfunction with an ejection fraction of ?45% occurring in the later stages of pregnancy or soon after delivery. Although various risk factors have been identified, the exact cause of the disease is unknown. Unlike most countries in the European region, Turkey has yet to determine the current PPCM burden. A registry for this purpose does not exist. To close this gap, the A RegisTry of pEripartuM cardIomyopathy in Turkish patientS (ARTEMIS-I and ARTEMIS-II), was planned and endorsed by the Turkish Society of Cardiology. The aim of this manuscript is to describe the rationale and design of the ARTEMIS-I and ARTEMIS-II registries. Methods:ARTEMIS was designed to be the nationwide PPCM registry of Turkey, with the goal of identifying problems and opportunities while improving quality and consistency in the medical care of PPCM patients. A second goal is to determine the clinical characteristics pertinent to patients in this region. The ARTEMIS registry will consist of 2 arms. All secondary and tertiary cardiology centers have been electronically invited to participate in ARTEMIS-I, which will be conducted to assess the current standard of care and outcome measures. Centers will be asked to enroll PPCM patients admitted to their clinic in last 5 years retrospectively. Eligibility criteria will consist of pregnant or early postpartum woman without a previous history of heart failure (HF) or known pathology associated with HF, LV ejection fraction ?45%, and exclusion of other causes of LV systolic dysfunction. ARTEMIS-II will consist of the prospective enrollment of patients. Conclusion: The nationwide PPCM registries, ARTEMIS-I and ARTEMIS-II, are designed to determine the current status of medical care, provide insights into nature of the disease, and suggest solutions on how to improve care and outcomes in these patients. © 2018 Turkish Society of Cardiology.en_US
dc.description.sponsorshipNovartis Actelion Pharmaceuticals Sanofi Pfizer Bayer Schering Amgen Bayer Servier Boehringer Ingelheim Abbott Laboratories GlaxoSmithKline Merck Daiichi Sankyo Companyen_US
dc.description.sponsorshipConflict-of-interest: Prof. Meral Kayıkçıoğlu, M.D., has received honoraria (lectures and counseling) and / or research funding from Abbott, Abdi İbrahim, Actelion, Aege-rion, Amgen, Bayer Schering, Merck, Sanofi, Pfizer, Recor-dati; Prof. Lale Tokgözoğlu, M.D., has received honoraria / consultancy fees from Merck, Amgen, Astra, Novartis, Abbott, Daiichi Sankyo, Pfizer, Actelion, Servier, Sanofi, Boehringer Ingelheim, Bayer, GlaxoSmithKline, Menarini, Kowa, Aegerion, and Synageva; Ferit Onur Mutluer, M.D., None; Prof. Dilek Ural, M.D., has received honoraria (for lectures and consultancy) from Abdi İbrahim, Amgen, Merck, and Novartis during the last 2 years; Assoc. Dr. Mu-rat Biteker, M.D., has received honoraria (for lectures and consultancy) from Abbott, Abdi İbrahim, Bayer, and Pfizer for the last 2 years.en_US
dc.item-language.isoengen_US
dc.publisherTurkish Society of Cardiologyen_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPeripartum Cardiomyopathyen_US
dc.subjectRegistryen_US
dc.subjectTurkeyen_US
dc.titleTürkiye’deki peripartum kardiyomiyopati kayıt çalışmalarının temeli ve tasarımı: ARTEMIS-I ve ARTEMIS-II çalışmalarıen_US
dc.item-title.alternativeThe rationale and design of the national peripartum cardiomyopathy registries in Turkey: The ARTEMIS-I and ARTEMIS-II studies [Türkiye’deki peripartum kardiyomiyopati kayıt çalışmalarının temeli ve tasarımı: ARTEMIS-I ve ARTEMIS-II çalışmaları]en_US
dc.item-typearticleen_US
dc.contributor.departmenten_US
dc.contributor.departmentTempKayıkçıoğlu, M., Department of Cardiology, Ege University, Faculty of Medicine, İzmir, Turkey -- [Tokgözoğlu, L., Department of Cardiology, Hacettepe University, Faculty of Medicine, Ankara, Turkey -- [Mutluer, F.O., Department of Cardiology, Koç University, Faculty of Medicine, İstanbul, Turkey -- [Ural, D., Department of Cardiology, Koç University, Faculty of Medicine, İstanbul, Turkey -- [Biteker, M., Department of Cardiology, Sıtkı Koçman University, Faculty of Medicine, İstanbul, Turkeyen_US
dc.identifier.doi10.5543/tkda.2018.53248
dc.identifier.volume46en_US
dc.identifier.issue1en_US
dc.identifier.startpage39en_US
dc.identifier.endpage46en_US
dc.relation.journalTurk Kardiyoloji Dernegi Arsivien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster